VISTA: a novel immunotherapy target for normalizing innate and adaptive immunity
MA ElTanbouly, W Croteau, RJ Noelle, JL Lines - Seminars in immunology, 2019 - Elsevier
MA ElTanbouly, W Croteau, RJ Noelle, JL Lines
Seminars in immunology, 2019•ElsevierV-domain Ig suppressor of T cell activation (VISTA) is a novel checkpoint regulator with
limited homology to other B7 family members. The constitutive expression of VISTA on both
the myeloid and T lymphocyte lineages coupled to its important role in regulating innate and
adaptive immune responses, qualifies VISTA to be a promising target for immunotherapeutic
intervention. Studies have shown differential impact of agonistic and antagonistic targeting
of VISTA, providing a unique landscape for influencing the outcome of cancer and …
limited homology to other B7 family members. The constitutive expression of VISTA on both
the myeloid and T lymphocyte lineages coupled to its important role in regulating innate and
adaptive immune responses, qualifies VISTA to be a promising target for immunotherapeutic
intervention. Studies have shown differential impact of agonistic and antagonistic targeting
of VISTA, providing a unique landscape for influencing the outcome of cancer and …
Abstract
V-domain Ig suppressor of T cell activation (VISTA) is a novel checkpoint regulator with limited homology to other B7 family members. The constitutive expression of VISTA on both the myeloid and T lymphocyte lineages coupled to its important role in regulating innate and adaptive immune responses, qualifies VISTA to be a promising target for immunotherapeutic intervention. Studies have shown differential impact of agonistic and antagonistic targeting of VISTA, providing a unique landscape for influencing the outcome of cancer and inflammatory diseases.
Elsevier